Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract

Sabine Ottinger1, Anne Klöppel, Vanessa Rausch

  • 1Molecular OncoSurgery, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany.

Insights

Marine sponge extracts, particularly from Crambe crambe, show promise in targeting cancer stem cells (CSCs) and overcoming therapy resistance in pancreatic and prostate cancers. This research paves the way for novel CSC-specific chemotherapeutic drug development.

Area of Science:

  • Marine Biology
  • Cancer Research
  • Pharmacology

Background:

  • Cancer stem cells (CSCs) drive tumor resistance to conventional therapies, notably in pancreatic and advanced prostate cancers.
  • Novel therapeutic strategies targeting CSCs are crucial for improving patient outcomes.
  • Marine sponges are a rich source of unexplored compounds with potential antineoplastic activity.

Purpose of the Study:

  • To investigate the potential of marine sponge extracts to eliminate CSC characteristics.
  • To evaluate the efficacy of Crambe crambe (CR) extract against pancreatic and prostate CSCs.
  • To assess CR's ability to overcome therapy resistance and reduce tumor initiation.

Main Methods:

  • Crude methanolic extracts from 11 sponge species were prepared.
  • Established pancreatic and prostate CSC lines were treated with extracts.
  • Assays included apoptosis, cell cycle, side population, colony/spheroid formation, migration, and in vivo tumorigenicity.
  • CR extract was tested at dilutions up to 1:1,000.

Main Results:

  • CR extract significantly reduced tumor cell viability at a 1:1,000 dilution, with lower toxicity to normal cells.
  • CR inhibited CSC self-renewal, apoptosis resistance, and proliferation, including in gemcitabine-resistant cells.
  • CR pretreatment reduced tumorigenicity in vivo and enhanced gemcitabine efficacy.

Conclusions:

  • Crambe crambe extract contains substances that target CSC characteristics, potentially enhancing standard cancer therapy.
  • Further isolation of bioactive metabolites from CR is warranted for developing new CSC-specific chemotherapeutic drugs.

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...